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Divergent Trends in Survival and Readmission
Following a Hospitalization for Heart Failure in the
Veterans Affairs Health Care System 2002 to 2006
Paul A. Heidenreich, MD, MS,*† Anju Sahay, PHD,* John R. Kapoor, MD, PHD,†
Michael X. Pham, MD,*† Barry Massie, MD‡§
Palo Alto, Stanford, and San Francisco, California
Objectives This study sought to determine recent trends over time in heart failure hospitalization, patient characteristics,
treatment, rehospitalization, and mortality within the Veterans Affairs health care system.
Background Use of recommended therapies for heart failure has increased in the U.S. However, it is unclear to what extent
hospitalization rates and the associated mortality have improved.
Methods We compared rates of hospitalization for heart failure, 30-day rehospitalization for heart failure, and 30-day
mortality following discharge from 2002 to 2006 in the Veterans Affairs Health Care System. Odds ratios for
outcome were adjusted for patient diagnoses within the past year, laboratory data, and for clustering of patients
within hospitals.
Results We identified 50,125 patients with a first hospitalization for heart failure from 2002 to 2006. Mean age did not
change (70 years), but increases were noted for most comorbidities (mean Charlson score increased from 1.72
to 1.89, p  0.0001). Heart failure admission rates remained constant at about 5 per 1,000 veterans. Mortality
at 30 days decreased (7.1% to 5.0%, p  0.0001), whereas rehospitalization for heart failure at 30 days in-
creased (5.6% to 6.1%, p  0.11). After adjustment for patient characteristics, the odds ratio for rehospitaliza-
tion in 2006 (vs. 2002) was 0.54 (95% confidence interval [CI]: 0.47 to 0.61) for mortality, but 1.21 (95% CI:
1.04 to 1.41) for heart failure rehospitalization at 30 days.
Conclusions Recent mortality and rehospitalization rates in the Veterans Affairs Health Care System have trended in opposite
directions. These results have implications for using rehospitalization as a measure of quality of care. (J Am
Coll Cardiol 2010;56:362–8) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.02.053f
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Ceart failure is a common chronic disease marked by
requent exacerbations often resulting in hospitalization and
eath (1,2). At 40 years of age, the lifetime risk of
eveloping heart failure is 1 in 5 (1). It has been the number
ne reason for admission among Medicare patients and
hose in the Veterans Affairs (VA) Health Care System (3).
eadmission for heart failure occurs in 20% of patients
ithin 30 days of discharge in those over age 65 years in the
edicare health care system. The high rate of hospitaliza-
ion is a major contributor to the estimated $37.2 billion in
ost of heart failure care in the U.S. for 2009 (1).
rom the *VA Palo Alto Health Care System, Palo Alto, California; †Department of
edicine, Stanford University, Stanford, California; and the ‡San Francisco VA
edical Center and the §Department of Medicine, University of California at San
rancisco, San Francisco, California. Supported by grants from the Veterans Affairs
ealth Services Research Development Office (CHF QUERI-04-326). Views
xpressed are those of the authors and not necessarily those of the Department of
eterans Affairs or other affiliated organizations.d
Manuscript received October 19, 2009; revised manuscript received January 4,
010, accepted February 1, 2010.There are multiple treatments known to prolong survival
or patients with heart failure, and many of these interven-
ions have been incorporated into the management of these
atients (2). In the VA Health Care System, use of certain
uideline-recommended treatments is now at a high level
4). However, it is unclear if the increased performance on
rocess of care measures for hospitalized patients has led to
mprovements in outcome.
See page 369
The purpose of this study was to determine if recent
ortality and readmission rates have improved within the
A Health Care System.
ethods
atients. We used data from the VA’s National Patient
are Database, which includes both inpatient (discharge
iagnoses, major procedures) and outpatient data (diag-
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July 27, 2010:362–8 Trends in Heart Failure Outcomeoses, location of encounter). We included the first admis-
ion per patient with the principal discharge diagnosis of heart
ailure (International Classification of Diseases-9th Revision
ICD-9] 428.xx, 429.3, 402.01, 402.11, 402.91, 425.xx, or
iagnosis-related group of 127), the admission occurred from
002 to 2006, and the patient was at least 18 years of age. We
xamined data back to 1999 to exclude prior heart failure
dmissions. Hospitalizations at non-VA facilities but paid by
he VA (8% of all heart failure admissions) were included.
In secondary analyses, we included all heart failure
ospitalizations from 2002 to 2006 (incident and prevalent
ases combined).
xclusions. In secondary analyses, hospitalizations were
xcluded if the patient was admitted to a non-VA facility
but care paid by the VA, 8%). This exclusion did not
mportantly change the results, and therefore, all first
dmissions were included in the primary analysis.
atient characteristics. Prior diagnoses were defined as any
npatient discharge diagnosis (primary or secondary) or at least
outpatient encounters with the diagnosis in the year prior to
dmission. Comorbid conditions were defined using ICD-9-
linical Modification diagnostic coding of the Charlson co-
orbidity criteria (5). Additional comorbidities (not included
n the Charlson score) were defined as follows: atrial fibrillation
r flutter (ICD-9 427.3x), hypertension (ICD-9 401 to 405),
schemic heart disease (ICD-9 410 to 414), and depression
ICD-9 300.4, 301.12, 309.0, 309.1, 311).
Laboratory data were obtained for serum creatinine,
lood urea nitrogen, sodium, blood hemoglobin, hemoglo-
in A1C, B-type natriuretic peptide, and troponin T or I.
e used the value closest to admission that was obtained
uring hospitalization or during the week before admission
or all values except troponin and hemoglobin A1C. For
roponin, we used the highest value during admission. For
emoglobin A1C levels, we used the value closest to
dmission that was obtained during hospitalization or dur-
ng the month before admission. Troponin T or I values
ere classified as below or above the detection threshold.
Medication data were obtained using VA pharmacy
ecords for filled prescriptions. We examined 2 periods: 180
ays before admission, and 90 days following discharge.
atients were included in the analysis of medication use for
given period if they had at least 1 filled prescription for any
edication during that time.
ollow-up. We used the VA’s Beneficiary Identification
ecords Locator Subsystem death file and the Social Secu-
ity Death Index to determine survival. The primary out-
ome was survival at 30 days following admission. Second-
ry mortality outcomes included in-hospital survival, and
urvival at 1 year. Other secondary outcomes included
eadmission rates at 30 days. Hospitalizations were catego-
ized as all cause, heart failure (primary or secondary
iagnosis at discharge), or primary heart failure (primary
iagnosis at discharge). We determined VA office (face-to-
ace) visits during 14 days following discharge for those alive
t discharge.tatistics. For comparing 2002
nd 2006 results, Pearson chi-
quare analysis was used to
valuate categorical variables at
nd t tests were used to evaluate
ifferences in continuous vari-
bles. A test for trend was used
o evaluate differences across all
ears, 2002 to 2006. We used
ogistic regression and general-
zed estimating equations to adjust differences in time-
pecific mortality and readmission for patient character-
stics while controlling for clustering of patients within
acilities. A 2-sided p value 0.05 was considered statis-
ically significant.
esults
eart failure hospitalizations. The study population con-
isted of 50,125 patients hospitalized with a primary dis-
harge diagnosis of heart failure from 2002 through 2006.
he admission rate remained relatively constant at about 5
eart failure admissions per 1,000 patients per year that
eceived treatment within the VA (Fig. 1). However, the
otal number of patients hospitalized with a primary dis-
harge diagnosis of heart failure increased from 9,655 in
002 to 10,151 in 2006, which was proportional to the
ncrease in patients seeking care within the VA system.
atient characteristics. Changes in patient characteristics
f those hospitalized with heart failure over time are shown
n Table 1. The majority of patients (90%) were men and
2% to 24% of those were reported to be black. However,
ace was available for only 80% of patients. Approximately
ne-half of the patients had a prior diagnosis of heart failure
s an outpatient, close to 40% had a prior diagnosis of
Figure 1 Heart Failure Admission Rates per 100,000
VA Population Are Displayed From 2002 to 2006
Heart failure is defined as a primary discharge diagnosis of heart failure. The
Veterans Affairs (VA) population is defined as the total number of unique indi-
viduals seeking care at the VA Health Care System. This includes 6% of hospi-
talizations that occurred at non-VA facilities but were paid by the VA. The slight
trend in more admissions is statistically significant (p  0.001).
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ICD-9  International
Classification of Diseases-
9th Revision
VA  Veterans Affairs
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Trends in Heart Failure Outcome July 27, 2010:362–8schemic heart disease, and one-third had diabetes. In-
reases in comorbid disease coding over time was noted for
ost diagnoses, though prior ischemic heart disease and
hronic obstructive pulmonary disease remained stable and a
istory of myocardial infarction decreased from 2002 to 2006.
he summary Charlson comorbidity score, based on comor-
idities during the index admission, increased from 1.72 to
.89 (p  0.0001). In the year before the first heart failure
dmission, 27% were hospitalized for nonheart failure diag-
oses in 2002 compared with 26% in 2006 (p  0.27).
Laboratory data (Table 2) were available for the vast
ajority of patients (80%) for sodium, hemoglobin, cre-
tinine, blood urea nitrogen and troponin. Values for
emoglobin A1C were only available in one-third and
-type natriuretic peptide values in a little less than one-half
f patients in 2006. From 2002 to 2006, there were slight
rends in Characteristics of Patients Hospitalizedith Heart F ilure in he VA Health Care System,002 and 2006
Table 1
Trends in Charact ristics of Patients Hospitalized
With Heart Failure in the VA Health Care System,
2002 and 2006
2002 2006 p Value
n 9,665 10,151
Age, yrs 69.5 12 69.5 12 0.93
Male sex 98% 98% 0.75
Black race* 22% 24% 0.0002
Diagnoses in the year before
admission
Acute myocardial infarction 8.4% 7.9% 0.21
Any ischemic heart disease 37.7% 38.4% 0.27
Diabetes 32.1% 34.7% 0.0001
Heart failure 45.5% 51.3% 0.0001
Hypertension 70.2% 78.5% 0.0001
Atrial fibrillation or flutter 17.6% 20.7% 0.0001
Chronic obstructive
pulmonary disease
24.5% 24.3% 0.78
Kidney disease 8.9% 12.9% 0.0001
Malignancy 9.4% 10.0% 0.11
Depression 9.1% 11.3% 0.0001
Charlson comorbidity score
(index admission)
1.72 2.1 1.89 2.2 0.0001
Race available for 15,790 (80%).
VA  Veterans Affairs.
rends in Characteristics of Patients With airst Hospitaliz tion for Heart Failure in eA Health Care System
Table 2
Tr nds in Char cteristics of Patients With a
First Hospitalization for Heart Failure in the
VA Health Care System
Laboratory Values* 2002 2006 p Value
Sodium 130 mEq/dl 3.5% 3.0% 0.06
Hemoglobin 10 mg/dl 12.0% 12.2% 0.67
Creatinine 2.0 mg/dl 15.8% 14.8% 0.05
Blood urea nitrogen 40 mg/dl 15.9% 14.6% 0.02
B-type natriuretic peptide 400 pg/dl N/A 73.5% N/A
Elevated troponin (T or I) N/A 51.5% N/A
Hemoglobin A1C 8% 26.4% 23.8% 0.03
Data available for the following: sodium (90%, n  17,742), hemoglobin (84%, n  16,598),
reatinine (84%, n  16,692), blood urea nitrogen (87%, n  17,309), B-type natriuretic peptide
44% for 2006, n 4,477), troponin T or I (87% for 2006, n 8,827), and hemoglobin A1C (28%,
 5,630).
N/A  data not available; VA  Veterans Affairs. Aecreases in the fraction of patients with elevated blood urea
itrogen and hemoglobin A1C. Of those tested in 2006,
ne-half had elevated troponin and 72% had markedly
levated B-type natriuretic peptide (400 pg/ml). Although
ata on weight were not available, coded obesity increased
rom 10% in 2002 to 12% in 2006 (p  0.0001).
Medication data were available for 87% of patients during
he 6 months before admission and in 89% during the 3
onths following admission (Table 3). Large increases were
een for beta-blockers, largely due to an increase in those
ecommended by guidelines (carvedilol, metoprolol succi-
ate, or bisoprolol). Use of angiotensin-receptor blockers
ncreased whereas use of angiotensin-converting enzyme
ACE) inhibitors and loop diuretics changed minimally. In
ontrast, use of digoxin dropped markedly. During the 3
onths following discharge, similar trends in medication
se were noted.
OSPITALIZATION TRENDS. Heart failure hospitalization
utcomes are shown in Table 4. Length of stay decreased by
pproximately 1 day (7.1 to 5.9 days) from 2002 to 2006
Table 4), though right heart catheterization, coronary
ngiography, implantable cardioverter-defibrillator place-
ent, and cardiac resynchronization therapy during hospi-
alization all increased slightly. The fraction of patients
ischarged home was over 85%, and this value increased
ver time. Approximately one-half of patients had a face-
o-face follow-up visit within 14 days, and this number
ncreased only slightly from 2002. Rehospitalization at 30
ays in 2006 was 5.6% for heart failure (primary diagnosis)
nd 16.5% for any cause. Rehospitalization rates for heart
ailure increased slightly but significantly (p  0.001) over
ime from 2002 to 2006 (Fig. 2). Total hospitals days over
he 1 year following admission were not significantly dif-
erent (Table 4). A length of stay above 5 days was
rends in Medication Use Before and After airst Hospitalization for Heart Failure in heA Health Care System
Table 3
Tr nds in M dication Use Before and After a
First Hospitalization for Heart Failure in the
VA Health Care System
2002 2006 p Value
Medication use in the 6 months before admission
Patients with any prescription, n 8,292 8,910
Beta-blocker, any 44% 62% 0.0001
Carvedilol, metoprolol succinate, or bisoprolol 7% 19% 0.0001
ACE inhibitor 55% 55% 0.52
Angiotensin-receptor blocker 6% 10% 0.0001
Loop diuretic 54% 50% 0.002
Digoxin 22% 14% 0.0001
Medication use in the 3 months following discharge
Patients with any prescription, n 8,617 9,174
Beta-blocker, any 54% 70% 0.0001
Carvedilol, metoprolol succinate, or bisoprolol 19% 38% 0.0001
ACE inhibitor 61% 58% 0.0001
Angiotensin-receptor blocker 6% 10% 0.0001
Loop diuretic 71% 70% 0.0001
Digoxin 30% 18% 0.0001CE  angiotensin-converting enzyme; VA  Veterans Affairs.
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July 27, 2010:362–8 Trends in Heart Failure Outcomeignificantly associated with readmission for any cause at 30
ays (18% vs. 14% for those with a length of stay 5 days,
 0.0001) but not for readmission with heart failure as the
rimary diagnosis (5.8% vs. 5.5%, p  0.33).
When all heart failure admissions were included in the
enominator, readmissions were much higher (22.5%),
ndicating that those hospitalized for heart failure for the
rst time are less likely to be readmitted than those with
rior heart failure admissions.
URVIVAL TRENDS. In 2002, mortality was 7.1% at 30 days
nd 28% at 1 year following an admission for heart failure.
y 2006, survival following a heart failure admission im-
Figure 2 Trends in 30-Day Rehospitalization Rates
Are Displayed From 2002 to 2006
There are slight but significant increases in rehospitalization for all-cause
admission, heart failure (HF) as a primary or secondary cause, and HF as the
primary cause (p  0.001 for each).
rends in Procedure Use and Outcome foratients With a First Hospitalization for Heart Failuren he VA Health Care Sys em
Table 4
Tr nd in Proc dure Use and Outcom for
Patients With a First Hospitalization for Heart Failure
in the VA Health Care System
Outcome 2002 2006 p Value
n 9,201 10,151
Length of stay, days, mean 7.1 19 6.2 22 0.002
Right heart catheterization* 3.0% 3.5% 0.04
Coronary angiography* 4.9% 7.3% 0.0001
ICD implanted* 0.2% 2.1% 0.0001
CRT implanted* 0.0% 0.45% 0.0001
Discharge to home 85.6% 88.7% 0.0001
Clinic follow-up within 14 days 51% 53% 0.0007
30-day heart failure rehospitalization† 5.6% 6.1% 0.11
30-day all-cause readmission 16.5% 16.7% 0.71
30-day all-cause readmission
(all hospitalizations)‡
22.5% 22.5% 0.92
Hospital days (year following admission),
mean  SD
7.7 17 7.3 16 0.06
In-hospital mortality 4.7% 2.8% 0.0001
30-day mortality 7.1% 5.0% 0.0001
1-year mortality‡ 27.7% 24.3% 0.0001
Excludes patients hospitalized at non-VA facilities. †Defined as a readmission with a principal
iagnosis of heart failure. ‡Denominator expanded to include all hospitalizations.
CRT  cardiac resynchronization therapy; ICD  implantable cardioverter-defibrillator; VA 
eterans Affairs.hroved at multiple time points, including in-hospital, 30
ays, and 1 year following admission (Table 4, Fig. 3). To
etermine if the prognostic value of coded diagnoses
hanged from 2002 to 2006 (which might occur if coding
ecame more aggressive), we determined the odds ratio for
n increase in the Charlson comorbidity score adjusted for
ge separately for 2002 and 2006. The odds ratio for 1-year
ortality for a 1 point increase in the Charlson score was
imilar in 2002 (1.16, 95% confidence interval [CI]: 1.12 to
.19) and 2006 (1.15, 95% CI: 1.11 to 1.19).
ULTIVARIATE ANALYSIS. After adjustment for patient
haracteristics including laboratory values, a significant reduc-
ion in mortality was observed from 2002 to 2006 (Fig. 4).
fter adjustment for patient characteristics, laboratory val-
es, and clustering of patients within hospitals, the odds
atio for a heart failure rehospitalization at 30 days increased
lightly over time (1.21, 95% CI: 1.04 to 1.41 for 2006 vs.
002). In contrast, the risk of death at 30 days following
dmission dropped markedly in 2006 versus 2002 (odds
atio: 0.54, 95% CI: 0.47 to 0.61) (Fig. 4). Further adjust-
ent for the increase in use of potentially life-prolonging
edication (beta-blockers, ACE inhibitors, angiotensin-
eceptor blockers) increased the odds ratio for mortality by
% (p  0.1).
UTCOME BY AGE GROUP. Heart failure readmission and
urvival by age group is shown in Figures 5A and 5B.
eadmission rates for heart failure were slightly higher in
he older and younger age groups, but there were no clear
ifferences over time. Mortality was reduced from 2002 to
006 in all age groups.
iscussion
he VA Health Care System has been known to provide
0.0%
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12.0%
16.0%
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M
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In Hospital 30-Day 90-Day
Figure 3 Trends in Survival at Different Time Points
Are Displayed for 2002 to 2006
Significant decreases in mortality were seen at discharge, 30 days
from admission, and 1 year following admission (p  0.001 for each).igh levels of recommended process of care for heart failure
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Trends in Heart Failure Outcome July 27, 2010:362–8s determined by performance measures from the Center for
edicare and Medicaid Services (4). However, it has been
ess clear if outcomes such as mortality or rehospitalization
ave improved. Our study finds that survival has improved
ollowing a VA heart failure hospitalization from 2002 to
006 but with a probable increase in rehospitalization rates.
t should be noted that the rehospitalization data are
ncomplete because we could not determine trends in
on-VA readmissions for heart failure that were not paid by
he VA.
Our finding of reduced mortality following an admission
or heart failure is consistent with improved in-hospital and
ischarge treatment for heart failure. Other studies of VA
opulations have noted increased use of beta-blockers and
CE inhibitors over time (6,7), and similar improvements
n heart failure care have been seen in the general popula-
ion. The CHS (Cardiovascular Health Study) of older
mericans with heart failure found that use of ACE
nhibitors increased 2.3% per year and beta-blocker use
ncreased 2.4% per year from 1989 to 2000 (8). Additional
tudies are needed to determine how much of the decline in
bserved mortality rates can be explained by increased use of
uideline-recommended medications.
Several potential explanations for the observed decrease
n mortality are unrelated to improved care. First, patients
ay be less ill. Laboratory data of renal function, hemoglobin,
nd sodium suggested that severity of disease may have
ecreased slightly. However, the vast majority of coded comor-
idities increased over time. The Charlson comorbidity score,
Figure 4 Adjusted Trends in 30-Day Rehospitalization (for a Pri
Mortality decreased while rehospitalization for heart failure (HF) remained flat or s
secondary diagnosis of HF (data not shown). The c-statistic for the models was 0.
for demographics, prior diagnoses and laboratory values, and clustering of patientmeasure of comorbidities during the index admission in- 2reased significantly from 2002 to 2006. Reduced mortality
ould also be explained by a higher fraction of elective hospi-
alizations for devices such as defibrillators. Although we could
ot determine the reason for admission, few patients under-
ent device placement during hospitalization.
Our finding that comorbidities increased over time sug-
ests that patients hospitalized in 2006 were more ill than
hose hospitalized earlier. This increase in risk could be
xplained by providers managing more heart failure as an
utpatient, thus raising the illness threshold for admission.
hart review data from non-VA U.S. populations have also
ound that hospitalized patients with heart failure are
ncreasingly at higher risk of death (9). Our results are also
onsistent with data from Minnesota that indicate an
ncrease in hypertension and diabetes among hospitalized
atients with heart failure (9). However, it is also possible
hat the increase was due to more aggressive coding without
true change in comorbidity. The latter was suggested by
he slight decrease in abnormal lab values from 2002 to
008. To further evaluate this issue, we compared the
redictive value of the Charlson comorbidity score for
atients hospitalized in 2002 with those hospitalized in
006 (more coded diagnoses). If coding practice became
ore aggressive (e.g., less severe renal dysfunction now
oded as renal failure), then we would expect that coded
iagnoses would become less predictive of mortality. We
ound that Charlson score remained similarly predictive of
ortality (odds ratio: 1.15 to 1.16 for 30-day mortality),
uggesting that coding practices were similar in 2002 and
Diagnosis of HF) and Mortality Rates From 2002 to 2006
increased over time. Similar results were seen for HF defined as a primary or
HF as a primary diagnosis and 0.75 for mortality. Models include adjustments
n facilities.mary
lightly
76 for
s withi006. Laboratory evidence for severity of illness (hypona-
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July 27, 2010:362–8 Trends in Heart Failure Outcomeremia, anemia, renal dysfunction) was not markedly
hanged from 2002 to 2006, suggesting that the severity of
eart failure was similar over this period.
Surprisingly, the trends in outcome for rehospitalization
nd mortality showed divergent patterns. Even though we
bserved clear decreases in mortality over time, readmission
ates actually increased slightly. An increase over time was
ore evident after adjustment for patient characteristics.
e would have expected both mortality and rehospitaliza-
ion to decrease if increases in guideline-recommended
reatment with beta-blockers and ACE inhibitors occurred
ecause these medications have led to reduced mortality and
ospitalizations in clinical trials (2). It is also possible that
hese recommended therapies have a more robust impact on
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Figure 5 Rates of All-Cause 30-Day Readmission
and Mortality at 30 Days Following Admission
(A) All cause 30-day readmission rates are shown by age group and year
(2002 vs. 2006). The differences over time are greatest for the younger age
groups. The differences are not statistically significant. Sample size for the
groups are age 18 to 54 years (n  2,318), age 55 to 64 years (n  4,672),
age 65 to 74 years (n  4,586), age 75 to 84 years (n  5,915), and age
85 years (n  1,581). (B) Mortality at 30 days following admission rates are
shown by age group and year (2002 vs. 2006). The differences are statistically
significant for all age groups except those age 18 to 54 years. There was no
significant interaction between age mortality differences between 2002 and
2006. Sample size for the groups are age 18 to 54 years (n  2,348), age 55
to 64 years (n  4,764), age 65 to 74 years (n  4,742), age 75 to 84 years
(n  6,247), and age 85 years (n  1,705).ortality than on readmission for heart failure. Whereas lncreased implantable cardioverter-defibrillator use would
e expected to lead to improved mortality without an impact
n heart failure hospitalizations, the increase use observed
as not great enough to explain the decline in mortality.
Studies in non-VA populations have found similar out-
ome trends. Mortality for patients with heart failure has
ecreased in U.S. Medicare (10), other U.S. (11–14), and
on-U.S. (15–17) populations up through the early 2000s.
ur findings indicate that this decline in mortality is also
resent in the VA and is continuing at least through 2006.
ur observation that rehospitalization rates are flat or
ncreasing is also consistent with most trend studies includ-
ng U.S. Medicare (10) and non-U.S. studies (15,17). Other
ata from U.S. male physicians (11) and data from Minne-
ota (14) report a stable incidence of heart failure, and recent
ata from the National Hospital Discharge Survey indicate
slight increase in hospitalization rates from 1995 to 2004
18). Other outcome studies of hospitalized heart failure
atients (19–21) have noted higher mortality rates. How-
ver, these studies examined populations with a higher
ortality with older age (mid-70s vs. 69.5 years for our
tudy) and with a higher fraction of white patients (shown
o have worse survival than nonwhite patients [22]).
The explanation for the lack of decline in heart failure
ehospitalization is unclear. Length of stay has declined
arkedly, and it is possible that patients are less stable at the
ime of discharge than in prior years. Although recom-
ended use of medical therapies at discharge have improved
ACE inhibitors and beta-blockers), other interventions may
ave more of an impact on rehospitalization such as intensive
atient education before discharge, early follow-up, and med-
cation reconciliation. It is unclear to what extent the use of
hese interventions has changed in the VA Health Care
ystem. Finally, the increase in survivors following discharge
ncreased the opportunity for readmission. Patients alive in
006 that would have died in 2002 are likely to have advanced
isease and a high rate of readmission.
Our study raises concerns that use of rehospitalization for
eart failure as a marker of poor care may be flawed, as it did
ot track with mortality in our study. It is possible that
any of the rehospitalizations were not “preventable.” A
rior randomized trial of intensive primary care follow-up
ollowing a discharge for chronic disease (including heart
ailure) noted that admissions actually increased though
atients rated their health better (23). It is also likely that
ome heart failure readmissions were lifesaving, and more
eadmissions or a longer length of stay for heart failure may
mprove the probability of long-term survival.
tudy limitations. Elderly veterans are eligible for Medi-
are and an unknown number were receiving dual care (VA
nd non-VA). Thus, the VA rehospitalization rate should
e considered a lower bound of the actual rehospitalization
ate. However, the relative changes over time in readmission
ates should not be affected by dual care unless the propor-
ion of dual care changed substantially over time. We
imited our cohort to patients initially hospitalized with a
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Trends in Heart Failure Outcome July 27, 2010:362–8rimary discharge diagnosis of heart failure. Whereas this
efinition has been shown to be highly specific (24), it will
ot include heart failure episodes that were not the primary
eason for admission. We did not have data on body mass
ndex, though changes in coded obesity were small. We also
id not have data on left ventricular ejection fraction and the
elative changes in mortality for those with and without
educed left ventricular ejection fraction are unknown.
inally, we did not have data on cause of death, and it is
ossible that trends in mortality from heart failure may have
iffered from trends in mortality from other causes.
onclusions
n summary, we found that the VA hospitalization rate for
eart failure has remained stable from 2002 to 2006.
lthough patients have increasingly more comorbidities,
heir mortality has declined significantly. In contrast, rehos-
italization rates for heart failure have not fallen and may
ave increased. Additional studies are needed to determine
he reasons for the decline in mortality and to determine
hich fraction of hospitalizations are preventable.
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